Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study.
Christopher AlbaShelly MalhotraStephanie HorsfallMatthew E BarnhartAdrie BekkerKaterina ChapmanColeen K CunninghamPatricia E FastGenevieve G FoudaKenneth A FreedbergAmeena GogaLusine R GhazaryanValériane LeroyCarlyn MannMargaret M McCluskeyElizabeth J McFarlandVincent Muturi-KioiSallie R PermarRoger ShapiroDevin SokLynda Stranix-ChibandaMilton C WeinsteinAndrea L CiaranelloCaitlin M DugdalePublished in: medRxiv : the preprint server for health sciences (2023)
Adding long-acting bNAbs to current standard-of-care prophylaxis would be cost-effective, assuming plausible efficacies and costs. The cost-effective target population would vary by setting, largely driven by maternal antenatal HIV prevalence and postpartum incidence.